Efficacy of Pembrolizumab and Lenvatinib in Patients With Anaplastic Thyroid Cancer
Status:
RECRUITING
Trial end date:
2026-06-25
Target enrollment:
Participant gender:
Summary
This pilot phase 2 study evaluate the effectiveness and safety of pembrolizumab and lenvatinib in patients with anaplastic thyroid cancer. Patients with anaplastic thyroid cancer who are treatment-naive (BRAF-negative) and who were previously treated with chemptherapy or targeted therapy are scheduled to undergo pembrolizumab and lenvatinib and evaluate the outcomes according to the primary and secondary endpoints.